Floatz logo

Bmn 255

Nonalcoholic Fatty Liver Disease

BioMarin PharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

139 Active assets in the Nonalcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Bmn 255 is also rated in:

nephrolithiasisDormant
CC
Indicative ·
43 / 100
View asset →
primary hyperoxaluriaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →